A ClickBank-distributed ACV and BHB gummy has surged in searches after a viral pre-meal satiety trend, but counterfeit listings cloud the market.

Kymera's oral IRF5 degrader matched or outperformed JAK inhibitors and biologics in a preclinical IBD model; Phase 1 human data are due in the

The Burlington-based vascular device maker reported Q1 2026 sales of $66.6m, with EPS up 42% year-on-year and full-year guidance raised.

Madrigal Pharmaceuticals has licensed ARO-PNPLA3 from Arrowhead, targeting a common genetic driver of MASH prevalent in Hispanic patients.

Madrigal's MASH therapy Rezdiffra has crossed blockbuster sales thresholds as the company expands its pipeline with a licensed siRNA targeting PNPLA3.

Expanded analysis of 69 nodular BCC patients showed 200µg D-MNA achieving 55% histological clearance at Day 57, prompting FDA end-of-phase talks.

Medline raised its full-year organic sales guidance to 8.5–9.5% despite a 25.8% drop in net income driven by tariff costs

The OTCQB-listed AI healthcare company more than doubled year-on-year quarterly revenues and cut its net loss by 72% as it prepares a

A US dietary supplement brand is marketing a five-ingredient botanical capsule at peripheral neuropathy sufferers seeking alternatives to gabapentin.

Novo Nordisk lifted its full-year outlook after Wegovy pill surpassed two million prescriptions since its January launch, despite US pricing pressure denting adjusted

Orchestra BioMed has drawn a scheduled $15m royalty-financing tranche from Ligand, bringing total Ligand capital to $40m to fund two pivotal cardiovascular device trials.

Pathos AI used its Foundry AI platform to identify and acquire Belgium-based DeuterOncology, whose DO-2 candidate showed 100% tumour shrinkage in a small